Autosomal Recessive Severe Congenital Neutropenia (SCN) due to CXCR2 Deficiency

Autosomal recessive severe congenital neutropenia due to CXCR2 deficiency is a very rare, inherited immune disorder present from infancy. Children are born with chronically low neutrophils—the white blood cells that are your “first responders” to bacteria. The problem is not that the bone marrow cannot make neutrophils. It can. The problem is neutrophils get trapped inside the marrow and do not reach the blood and tissues well enough. That trapping pattern is called myelokathexis (Greek for “retained marrow”). The medical reason is loss-of-function mutations in the CXCR2 gene, which encodes the CXCR2 receptor on neutrophils. Normally, CXCR2 senses chemoattractant signals (like IL-8/CXCL8 and related chemokines) and helps neutrophils exit the bone marrow and move to infection sites. When CXCR2 is defective on both gene copies (autosomal recessive), neutrophils fail to mobilize, blood counts stay low, and infections become frequent. This entity is now recognized as a distinct genetic cause of congenital neutropenia, different from the better-known WHIM syndrome (which is caused by CXCR4 gain-of-function, not CXCR2 loss). PMC+3Orpha+3haematologica.org+3

CXCR2-deficiency SCN is a very rare, inherited immune disorder. Children are born with extremely low levels of neutrophils (a type of white blood cell that fights bacteria). Because the CXCR2 receptor—a “traffic signal” on developing neutrophils—doesn’t work properly, neutrophils fail to develop and/or move out of the bone marrow normally. This causes frequent, sometimes severe, bacterial infections starting in infancy. The condition follows an autosomal-recessive pattern (a child inherits two faulty copies of CXCR2), and prevalence is well under 1 in a million. haematologica.org+3Orpha+3rarediseases.info.nih.gov+3

CXCR2 is a chemokine receptor (an IL-8/CXCL8 receptor) that guides neutrophil migration and helps control release from bone marrow. When it’s missing or not working, neutrophils don’t reach the bloodstream or tissues as they should, increasing infection risk. haematologica.org+2PMC+2

Researchers showed in people and in mouse models that CXCR2 and CXCR4 work like a push-pull pair: CXCR2 helps push neutrophils out, while CXCR4 helps hold them in the marrow. When CXCR2 is missing or weak, the “push” is gone, and neutrophils stay in—producing peripheral neutropenia and infection risk. PMC+1

Other names

• Autosomal recessive SCN due to CXCR2 deficiency

• CXCR2-related congenital neutropenia

• Biallelic CXCR2 loss-of-function neutropenia

• Myelokathexis-like congenital neutropenia (non-WHIM)

• Primary immunodeficiency due to CXCR2 mutation (rare) Orpha+1

Types

Because this is very rare, formal “types” are not standard. Clinicians usually describe it by severity, mutation, and clinical pattern:

1. Severe, persistent neutropenia from infancy with frequent serious infections (e.g., pneumonias, deep skin/soft tissue infections). Orpha+1

2. Moderate or fluctuating neutropenia with fewer infections—reported in some families depending on the exact CXCR2 variants. PMC

3. Genotype-defined subtypes: missense vs nonsense vs splice variants in CXCR2, which can affect receptor folding, surface expression, ligand binding, or signaling strength. (This helps explain why two children can look a bit different clinically.) haematologica.org

4. Myelokathexis-dominant phenotype (marrow retention pattern) without the warts or hypogammaglobulinemia typical of WHIM syndrome (CXCR4 GOF). Orpha+1

Causes

Note: This condition’s root cause is inherited CXCR2 loss-of-function on both gene copies. Items below break that root cause into concrete, mechanistic “causes” and recognized contributors that shape disease expression and severity.

1. Biallelic CXCR2 loss-of-function variants (missense, nonsense, frameshift, splice) that abolish or blunt receptor function. haematologica.org+1

2. Defective receptor folding → receptor degraded before reaching the cell surface. haematologica.org

3. Reduced surface expression of CXCR2 on neutrophils → weaker chemokine sensing. haematologica.org

4. Impaired ligand binding (e.g., to CXCL8/IL-8, CXCL1, CXCL2, CXCL5, CXCL6, CXCL7) so the “go” signal is never received. Cell

5. Faulty G-protein coupling or downstream signaling (e.g., ERK/AKT pathways), so receptor engagement fails to trigger movement. Cell

6. Failure of bone-marrow egress (the myelokathexis mechanism): neutrophils mature but remain trapped. PMC

7. CXCR2–CXCR4 imbalance: with a weak CXCR2 “push,” the normal CXCR4 “hold” dominates, increasing retention. PMC

8. Chemokine milieu mismatch: if ligands are present but the receptor is nonfunctional, guidance is lost. Cell

9. Modifier genes in the chemokine axis (e.g., regulators like CCRL2 in mice) can shape neutrophil trafficking efficiency. ASH Publications

10. Consanguinity/autozygosity increasing the chance of inheriting two defective copies in rare conditions. (General genetic principle for recessive disease.) Orpha

11. Recurrent bacterial exposure early in life, which reveals the underlying neutrophil defect with severe infections. Orpha

12. Bone-marrow microenvironment factors that cannot compensate for the missing CXCR2 signal. PMC

13. Neutrophil desensitization or receptor internalization dynamics—compounded when receptor is already weak. Cell

14. Aberrant neutrophil functional programs (e.g., altered NETs biology secondary to chemokine axis changes). PubMed+1

15. Coexisting variants in other SCN genes (rare) that might intensify phenotype or complicate diagnosis. ScienceDirect

16. Inflammation-induced stress that demands rapid neutrophil mobilization the body cannot deliver without CXCR2. Cell

17. Iatrogenic suppression (e.g., intercurrent medications that lower neutrophils) makes the congenital baseline worse. (General hematology practice.)

18. Nutritional stress or severe illness increasing infection risk when ANC is already low. (General pediatric ID principle.)

19. Delayed recognition leading to repeated infections and cumulative damage before diagnosis. Orpha

20. Diagnostic confusion with WHIM or ELANE-SCN, slowing correct, gene-specific management discussions. PMC+1

Symptoms and signs

1. Frequent bacterial infections from early infancy (ears, sinuses, lungs, skin). This reflects a chronically low absolute neutrophil count (ANC). Orpha

2. Pneumonia and lower respiratory infections that recur or linger. Orpha

3. Skin and soft-tissue abscesses, boils, or cellulitis that need antibiotics or drainage. Orpha

4. Oral ulcers, gingivitis, and periodontitis, because mouth bacteria flourish when neutrophils are scarce. (Common across neutropenias.) ScienceDirect

5. Fever during infections; sometimes high fever with chills. Orpha

6. Sepsis in severe cases, especially before diagnosis and prophylaxis. Orpha

7. Otitis media (ear infections), often repeated. Orpha

8. Sinus infections or chronic rhinosinusitis. (Common in neutropenia.) ScienceDirect

9. Swollen, tender lymph nodes during infections. (Reactive.)

10. Poor wound healing or delayed improvement after small cuts or procedures. (General neutropenia effect.)

11. Fatigue and reduced energy during infection clusters.

12. Poor weight gain or “failure to thrive” in infants with repeated serious infections. Orpha

13. No warts and no persistent lymphopenia—this helps distinguish from WHIM syndrome. Orpha+1

14. Hospitalizations for IV antibiotics due to severity of infections. Orpha

15. Anxiety for families related to recurrent, serious infections—an important psychosocial aspect clinicians address.

Diagnostic tests

To make this easy to follow, I’ll group tests into Physical Exam, Manual/bedside, Laboratory & Pathology, Electrodiagnostic/Functional instruments, and Imaging. Not every test is needed in every patient—clinicians choose based on history and local practice.

A) Physical Exam

1. General exam with vitals: fever, heart rate, breathing rate, oxygen level—helps judge infection severity at the bedside.

2. Skin exam: looking for cellulitis, abscesses, surgical scars that heal slowly, or recurrent boils.

3. Mouth and gums: ulcers, gingivitis, periodontitis—common in neutropenia. (Clues toward a chronic low-neutrophil state.) ScienceDirect

4. Lung exam: crackles or reduced air entry can suggest pneumonia; guides urgent imaging and antibiotics.

5. Liver/spleen/lymph nodes: palpation to detect enlargement or tenderness during infections.

B) Manual / Bedside

6. Temperature and sepsis screens (serial): detects dangerous infection early, which is critical in severe neutropenia.

7. Manual differential on a blood smear: a technologist looks under the microscope to count cells and check neutrophil maturity. In CXCR2 deficiency, peripheral blood is often paucicellular for neutrophils despite robust marrow production. Orpha

8. Absolute neutrophil count (ANC) calculation from CBC + differential. Persistent ANC <500/µL supports severe neutropenia. (Thresholds from standard hematology practice.)

9. Bedside wound/abscess evaluation: fluctuation suggests pus needing drainage plus cultures to guide therapy.

10. Infection source checklists (ears, sinuses, lungs, skin, urinary) to target cultures and imaging quickly.

C) Laboratory & Pathology

11. Complete blood count (CBC) with differential (serial): documents chronic neutropenia and tracks response to care. Orpha

12. Inflammatory markers (CRP, ESR, sometimes procalcitonin): help gauge infection severity and treatment response.

13. Blood and site cultures: identify bacteria and antibiotic sensitivities for targeted therapy. (Core ID practice.)

14. Bone marrow aspirate and biopsy: classically shows myeloid hyperplasia with retention of mature neutrophils (“myelokathexis”)—strong pathologic clue for a trafficking defect rather than a production failure. PMC

15. Flow cytometry for surface CXCR2 on neutrophils (if available): may show reduced receptor expression or abnormal staining. haematologica.org

16. Neutrophil chemotaxis assays to CXCR2 ligands (e.g., CXCL8/IL-8) in specialized labs: reduced migration supports a functional CXCR2 defect. haematologica.org

17. Targeted genetic testing: sequencing of CXCR2 to confirm biallelic loss-of-function variants; often ordered within an SCN gene panel (ELANE, HAX1, G6PC3, JAGN1, etc.) to avoid missing other causes. haematologica.org+2mayocliniclabs.com+2

18. Rule-out panels for look-alikes: e.g., CXCR4 for WHIM, ELANE for classic SCN, G6PC3 and others—because treatment and monitoring differ by gene. ScienceDirect+1

D) Electrodiagnostic / Functional instrumented tests

In hematology, there are few “electrodiagnostic” tests like those used in neurology. Here, the aim is instrumented function testing of neutrophils.

19. Flow-cytometric oxidative burst (DHR assay): rules out chronic granulomatous disease; normal DHR with neutropenia points back toward a trafficking problem like CXCR2 deficiency. (Standard immunology workflow.)

20. Real-time impedance-based migration assays (specialized centers): measure neutrophil movement across membranes; CXCR2-defective cells migrate poorly toward IL-8–like ligands. haematologica.org

21. Microfluidic time-lapse chemotaxis testing (research settings): visualizes cell tracking toward CXCR2 ligands; movement is blunted with CXCR2 LOF. haematologica.org

22. Advanced receptor signaling readouts (e.g., ERK phosphorylation after IL-8 stimulation in vitro): demonstrate impaired CXCR2 signal transduction. (Used in research reports that defined the entity.) haematologica.org

E) Imaging

23. Chest X-ray for suspected pneumonia; quick and available in most emergency settings.

24. Chest CT when pneumonia is recurrent or complications (abscess, bronchiectasis) are suspected.

25. Ultrasound of soft tissues or abdomen to locate abscesses and guide drainage safely.

26. MRI for suspected osteomyelitis or deep collections near joints/spine that CT or ultrasound might miss.

Non-pharmacological treatments (therapies & others)

1. Fever action plan at home
   Have a written plan for any temperature ≥38.0°C: check temperature, start urgent evaluation, and begin empiric antibiotics in medical care without delay. Early action saves lives because neutropenic bodies can’t localize infection. Purpose: reduce time to treatment; Mechanism: fast triage prevents bacteria from spreading. OUP Academic+1

2. Hand-hygiene coaching for caregivers
   Frequent, correct hand-washing and alcohol rubs for the child and carers cut down bacteria transfer from skin and surfaces. Purpose: block entry of germs; Mechanism: lowers bacterial load at contact points. PMC

3. Skin and oral care routine
   Daily gentle skin cleansing, prompt care for cuts, and soft-bristle tooth-brushing with fluoride reduce skin and mouth infections (common in SCN). Purpose: protect barrier tissues; Mechanism: decreases bacterial colonization and micro-breaks that can seed infection. PMC

4. Food-safety (“neutropenic diet”) habits
   Thorough produce washing, safe cooking temperatures, separate cutting boards, and avoiding high-risk raw foods reduce foodborne infections. Purpose: safer meals; Mechanism: lowers exposure to gut pathogens. Memorial Sloan Kettering Cancer Center

5. Dental check-ups and periodontal prevention
   Regular dental visits, fluoride varnish, and early treatment for gingivitis limit mouth ulcers and bacteremias. Purpose: fewer mouth sources of infection; Mechanism: reduces oral bacterial reservoirs. PMC

6. Wound care protocols
   Clean, cover, and monitor any skin break; seek care for redness, pain, or pus. Purpose: keep bacteria out; Mechanism: creates a physical barrier and reduces bacterial growth. PMC

7. Vaccination (inactivated vaccines as advised)
   Keep routine inactivated vaccines up to date (per local guidelines). Live vaccines are usually avoided during profound neutropenia unless an immunology team approves. Purpose: prevent vaccine-preventable infections; Mechanism: primes other arms of the immune system. PMC

8. Household infection control
   No sharing of toothbrushes/razors; clean high-touch surfaces; keep sick contacts at distance. Purpose: cut transmission; Mechanism: reduces exposure dose. PMC

9. School/daycare accommodations
   Plans for quick pickup with fever, minimizing exposure during local outbreaks, and allowing mask use. Purpose: reduce infection exposure; Mechanism: time-limited risk reduction when community infections rise. PMC

10. Environmental risk reduction
    Avoid poorly ventilated, crowded spaces during community outbreaks; careful pet hygiene; avoid litter box handling. Purpose: limit pathogen encounters; Mechanism: lowers inoculum and risky contacts. PMC

11. Central line care education (if needed)
    If a port/PICC is used, strict sterile technique for access, dressing changes, and flush schedules reduces bloodstream infection. Purpose: protect a direct bloodstream entry point; Mechanism: removes skin bacteria and biofilm risks. PMC

12. Thermometer and supplies at home
    Having a reliable digital thermometer and a “go-bag” (med list, recent counts, clinic contacts) prevents delays in seeking care. Purpose: speed; Mechanism: faster decision-making. OUP Academic

13. Proactive sinus/skin infection screening
    Early swabs, dental and ENT assessment when symptoms start. Purpose: catch infections sooner; Mechanism: earlier antibiotics. OUP Academic

14. Sun/skin protection
    Gentle emollients, sunscreen, and avoiding harsh chemicals keep skin intact. Purpose: maintain barrier; Mechanism: fewer micro-abrasions. PMC

15. Household food handling training
    Teach caregivers about refrigerator temperatures, leftovers timing, and cross-contamination. Purpose: safe kitchens; Mechanism: lowers bacterial growth. Memorial Sloan Kettering Cancer Center

16. Travel precautions plan
    Carry recent medical summary, avoid high-risk foods/water, and identify nearby hospitals. Purpose: safer travel; Mechanism: preserves emergency readiness. OUP Academic

17. Growth and nutrition monitoring
    Regular checks with dietitian to support growth; SCN infections can stunt growth; support calories and proteins. Purpose: resilience; Mechanism: supports healing and immunity. PMC

18. Caregiver vaccination
    Flu and other indicated shots for household members reduce the chance of bringing infections home. Purpose: cocoon protection; Mechanism: herd protection at home. PMC

19. Psychosocial support
    Counselling for stress and safety coaching helps families stick to plans. Purpose: adherence; Mechanism: improves consistency of protective behaviors. PMC

20. Specialist coordination
    Regular follow-up with hematology/immunology teams to adjust G-CSF, labs, and plans. Purpose: prevent crises; Mechanism: proactive surveillance. PMC

---

Drug treatments

Important: Only filgrastim (G-CSF) carries explicit U.S. FDA labeling for severe chronic neutropenia, including congenital forms. Other agents below are used for related situations (e.g., fever in neutropenia, prophylaxis, fungal/viral coinfections, or transplant contexts) and may be off-label in CXCR2-deficiency SCN. Your specialist team will individualize therapy. FDA Access Data+1

1. Filgrastim (Neupogen®, and biosimilars e.g., Zarxio®)
   Class: G-CSF. Purpose: Raise ANC and reduce infections in severe chronic neutropenia (SCN). How it works: Stimulates bone marrow neutrophil production and release. Dose/time: Labels describe higher requirements in congenital neutropenia; a common starting regimen is 6 mcg/kg twice daily s.c. for SCN (then titrate to the lowest dose that keeps ANC in a safe range). Side effects: Bone pain, splenic enlargement/rare rupture, ARDS (very rare), leukocytosis. Evidence: Long-term registry and label data show ANC rises within 1–2 weeks and infection reduction. FDA Access Data+3FDA Access Data+3FDA Access Data+3

2. Pegfilgrastim (Neulasta®)
   Class: Long-acting G-CSF. Purpose: Once-per-cycle support in chemotherapy settings; sometimes considered off-label in congenital neutropenia when daily injections are not feasible (specialist decision). Mechanism: Same receptor as filgrastim with PEG prolonging half-life. Dose: 6 mg s.c. per chemo cycle in labeled use. Notes: Splenic rupture warning; avoid 14 days before to 24 h after cytotoxic chemo. FDA Access Data+1

3. Sargramostim (Leukine®)
   Class: GM-CSF. Purpose: Myeloid reconstitution post-transplant and other labeled settings; occasionally considered when G-CSF response is inadequate (off-label for SCN). Mechanism: Broad myeloid stimulation. Dose: Per label varies by indication; monitor for fluid retention and pulmonary events. FDA Access Data+1

4. Tbo-filgrastim (Granix®)
   Class: G-CSF analog. Purpose: Chemo-induced neutropenia; off-label decisions in SCN are specialist-only. Mechanism/dose: Similar to filgrastim; safety includes hypersensitivity and rare splenic rupture. FDA Access Data+1

5. Broad-spectrum IV antibiotics for febrile neutropenia: Cefepime
   Class: 4th-gen cephalosporin. Purpose: First-line empiric therapy for fever in severe neutropenia. Mechanism: Blocks bacterial cell-wall synthesis; covers Pseudomonas. Dose/time: Hospital protocols per IDSA; start immediately with fever. Effects: Allergy, GI upset, rare encephalopathy. (Guideline-based use.) OUP Academic+1

6. Piperacillin–tazobactam
   Class: Antipseudomonal β-lactam/β-lactamase inhibitor. Purpose: Alternative first-line empiric IV antibiotic. Mechanism/dose: Rapid bactericidal activity; dosing per renal function. Effects: Allergy, electrolyte shifts. OUP Academic

7. Meropenem
   Class: Carbapenem. Purpose: Empiric therapy when resistant organisms or severe sepsis suspected. Mechanism: Broadest β-lactam coverage. Effects: Seizure risk is low; adjust for kidneys. OUP Academic

8. Vancomycin (add-on when needed)
   Class: Glycopeptide. Purpose: Add if catheter infection, MRSA risk, pneumonia, or skin/soft tissue signs. Mechanism: Cell-wall inhibition for gram-positive cocci. Effects: Nephrotoxicity, infusion reactions; monitor levels. OUP Academic

9. Levofloxacin (oral) for select outpatient low-risk fever
   Class: Fluoroquinolone. Purpose: Part of outpatient oral regimens in carefully selected low-risk adults (cancer setting)—protocol-driven; pediatrics differ. Mechanism: DNA gyrase inhibition. Effects: Tendon, QT, CNS warnings. Infectious Diseases

10. Amoxicillin–clavulanate (oral combination regimens)
    Class: β-lactam/β-lactamase inhibitor. Purpose: With a fluoroquinolone in certain low-risk fever pathways (adult cancer guidance). Effects: GI upset, allergy. Infectious Diseases

11. Trimethoprim–sulfamethoxazole (TMP-SMX)
    Class: Antifolate combo. Purpose: Bacterial prophylaxis or treatment of specific infections per specialist plan. Mechanism: Folate pathway blockade. Effects: Rash, cytopenias; monitor counts. (Guideline-context use.) idsociety.org

12. Fluconazole (antifungal)
    Class: Triazole. Purpose: Candidiasis treatment/prophylaxis in selected high-risk scenarios. Mechanism: Ergosterol synthesis inhibition. Effects: Drug interactions via CYP; monitor LFTs. (Guideline-context.) OUP Academic

13. Posaconazole / Voriconazole (antifungals)
    Class: Triazoles. Purpose: Mold-active prophylaxis/treatment in prolonged neutropenia per risk assessment. Mechanism: Ergosterol pathway. Effects: Hepatic, visual (voriconazole), interactions. OUP Academic

14. Echinocandins (micafungin/caspofungin)
    Class: β-glucan synthase inhibitors. Purpose: Empiric antifungal in persistent fever. Mechanism: Weakens fungal cell wall. Effects: Generally well-tolerated; LFTs. OUP Academic

15. Amphotericin B (liposomal)
    Class: Polyene. Purpose: Refractory suspected invasive fungal infection. Mechanism: Membrane pore formation. Effects: Nephrotoxicity; electrolyte loss; premedication often needed. OUP Academic

16. Acyclovir/Valacyclovir (antivirals)
    Class: Guanine analogs. Purpose: HSV/VZV prevention/treatment when indicated. Mechanism: Viral DNA chain termination. Effects: Renal dosing needed. OUP Academic

17. IVIG (immunoglobulin) in selected cases
    Class: Pooled antibodies. Purpose: Adjunct when specific antibody support is needed (specialist decision). Mechanism: Passive immunity. Effects: Headache, thrombosis risk; slow infusion. (Label-based safety/administration context.) OUP Academic

18. HSCT conditioning support medicines
    Purpose: In transplant pathways for cure (see surgeries below), regimens use agents like busulfan/fludarabine per transplant protocols; medicine choices are center-specific. ASH Publications+1

19. Pain control (acetaminophen; avoid masking fever before evaluation)
    Purpose: Comfort after procedures; do not pre-treat fevers before medical review. Mechanism: Antipyretic/analgesic. Note: Fever is a critical warning sign in SCN. OUP Academic

20. Specialist-directed use of alternative G-CSFs/analogs or GM-CSF
    When access, tolerance, or schedule drives the choice, clinicians may rotate or trial biosimilars/GM-CSF with careful monitoring. Decisions are individualized. FDA Access Data+2FDA Access Data+2

---

Dietary molecular supplements

Safety first: Supplements rarely raise neutrophils in congenital disorders; they are supportive for overall health. Use only under your clinician’s guidance, as some interact with medicines.

1. Vitamin D — supports bone, muscle, and immune modulation. Typical maintenance intakes vary by age; excessive doses can be harmful. Clinician-guided testing and dosing are best. Office of Dietary Supplements+1

2. Vitamin C — antioxidant; supports immune function and wound healing; meeting daily needs through food or supplements as advised is reasonable. Office of Dietary Supplements+1

3. Zinc — required for immune cell function; avoid overdose (can cause copper deficiency). Discuss dosing with your clinician. Office of Dietary Supplements+1

4. General immune-nutrition overview — ODS summary notes micronutrients (C, D, zinc) are necessary for immune function; benefit depends on deficiency status. Office of Dietary Supplements+1

5. Probiotics (caution) — data on safety during neutropenia are mixed; many centers avoid probiotic foods/supplements during severe neutropenia due to rare bacteremia risks; only use if your team recommends them. Blood Cancer UK+2ScienceDirect+2

6. Balanced protein (whey/medical nutrition shakes if needed) — helps tissue repair during/after infections; choose pasteurized, safe products per neutropenic diet guidance. Memorial Sloan Kettering Cancer Center

7. Omega-3 fatty acids (dietary sources) — may support general health; discuss supplement forms due to bleeding/interaction concerns. Office of Dietary Supplements

8. Folate/B-complex only if deficient — deficiency can worsen blood counts; test before supplementing. PMC

9. Iron only if iron-deficient — unneeded iron can increase infection risk; never self-start. PMC

10. Multivitamin at RDA levels — fills small gaps when appetite is poor; avoid mega-doses. Office of Dietary Supplements

---

Drugs for immunity boosting / regenerative / stem-cell

1. Filgrastim (G-CSF) — cornerstone for raising ANC in SCN; stimulates neutrophil production and release. Dosing individualized; monitor spleen and counts. FDA Access Data

2. Pegfilgrastim (long-acting G-CSF) — longer half-life; specialist may consider in select scenarios. Monitor splenic symptoms. FDA Access Data

3. Sargramostim (GM-CSF) — broad myeloid stimulant used post-transplant and in specific indications; sometimes considered when G-CSF response is suboptimal. FDA Access Data

4. HSCT conditioning agents (e.g., busulfan, fludarabine) — used around curative stem-cell transplant; not everyday medicines, but part of the regenerative pathway. ASH Publications

5. Antimicrobial prophylaxis “as immune support” — targeted antibacterials/antifungals reduce infection burden while counts are low; guided strictly by IDSA/ASCO risk assessment. OUP Academic

6. IVIG (selected scenarios) — provides passive antibodies when indicated; not a neutrophil-raiser but may reduce certain infections in select circumstances. OUP Academic

---

Surgeries / procedures

1. Allogeneic Hematopoietic Stem-Cell Transplant (HSCT)
   Why done: It is the only curative therapy for SCN when G-CSF fails, doses are excessive, or there’s progression toward MDS/AML. What happens: Healthy donor stem cells replace the child’s marrow. Outcomes: Modern, reduced-toxicity regimens have improved results; timing before malignant transformation is key. PMC+2ASH Publications+2

2. Central venous catheter (port/PICC) placement
   Why: Reliable access for IV antibiotics, transfusions, and blood tests in children with frequent infections. What: Small surgery to place a long-term line; strict sterile care reduces infection risk. PMC

3. Incision & drainage of abscesses
   Why: Neutropenic patients can develop deep skin/soft-tissue infections that need surgical drainage plus antibiotics. What: Small procedure to evacuate pus and speed healing. OUP Academic

4. ENT/dental procedures for chronic foci
   Why: Remove persistent sources (e.g., severe periodontitis/sinus disease) that seed recurrent infections. What: Targeted procedures paired with antimicrobial therapy. PMC

5. Bone-marrow evaluation (aspirate/biopsy)
   Why: Diagnose SCN, monitor response to G-CSF, and surveil for MDS/AML risk over time. What: Needle sampling from hip bone under local/sedation. PMC

---

Prevention tips

1. Treat any fever ≥38.0°C as an emergency. Go to care now. OUP Academic

2. Keep hand hygiene top-notch at home and school. PMC

3. Follow food-safety steps; avoid high-risk raw foods. Memorial Sloan Kettering Cancer Center

4. Maintain oral health; early dental care for ulcers/bleeding gums. PMC

5. Care for skin nicks quickly—clean, cover, watch. PMC

6. Keep vaccinations (inactivated) up-to-date as advised. PMC

7. Avoid sick contacts and crowded spaces during outbreaks. PMC

8. Have antibiotic plans and numbers for your team ready. OUP Academic

9. Growth & nutrition checks to support healing. PMC

10. Keep regular specialist follow-ups for labs and medication tuning. PMC

---

When to see a doctor

• Go now (emergency): Fever ≥38.0°C, shaking chills, fast breathing, chest pain, confusion, severe sore throat or mouth ulcers, painful skin redness/swelling, belly pain, vomiting that prevents fluids, extreme sleepiness, or any rapidly worsening symptom. Start empiric antibiotics promptly in medical care. OUP Academic

• Soon (within 24–48 h): New cough, ear pain, urinary burning, small skin pustules, mouth sores, or line-site redness—before they escalate. OUP Academic

• Routine: Growth/nutrition checks, vaccine review (inactivated), ANC monitoring, and periodic marrow assessments as your team recommends. PMC

---

Foods to focus on and to be careful with

What to eat (prepared safely):

1. Thoroughly washed fruits you can peel (bananas, oranges).

2. Well-cooked vegetables.

3. Pasteurized dairy (milk, cheese).

4. Well-cooked eggs.

5. Well-cooked chicken/fish/meat.

6. Legumes cooked until soft.

7. Whole grains (well-cooked rice, oats).

8. Olive/canola oil for calories.

9. Yogurt that is pasteurized and not labeled probiotic unless your clinician says it’s OK.

10. Plenty of safe fluids (boiled/treated water). Memorial Sloan Kettering Cancer Center+1

What to avoid (during severe neutropenia):

1. Raw or undercooked eggs.

2. Unpasteurized milk/cheese/juices.

3. Raw seafood/sushi.

4. Deli meats unless reheated steaming hot.

5. Unwashed raw produce and salad bars.

6. Sprouts (alfalfa, bean).

7. Buffet or lukewarm foods.

8. Probiotic” drinks or kefir unless approved.

9. Foods past use-by dates.

10. Cross-contaminated items (same cutting board as raw meat). Memorial Sloan Kettering Cancer Center+1

---

Frequently asked questions

1. Is CXCR2-deficiency SCN the same as WHIM syndrome?
   No. WHIM is usually due to CXCR4 variants. CXCR2-deficiency is a distinct, autosomal-recessive cause of chronic/severe neutropenia. PMC+1

2. Can children outgrow it?
   It’s genetic, so they don’t “outgrow” it, but many do well long-term with expert care and G-CSF; some need HSCT. PMC

3. What is the main medicine that helps?
   Filgrastim (G-CSF) is the primary labeled therapy for severe chronic neutropenia, including congenital forms. FDA Access Data

4. How fast does G-CSF work?
   ANC often rises within 1–2 weeks, with dose titrated to the lowest effective dose. FDA Access Data

5. Are there risks to long-term G-CSF?
   Benefits are large, but long-term SCN cohorts show a background risk for MDS/AML that requires monitoring; transplant is considered for high-risk cases. PMC+1

6. When is transplant considered?
   When response to G-CSF is poor, doses become very high, or there’s clonal evolution/MDS-AML risk. HSCT can be curative. PMC+1

7. Are live vaccines allowed?
   Usually avoided in profound neutropenia unless an immunologist approves; inactivated vaccines are encouraged. PMC

8. Do supplements fix neutropenia?
   No. Supplements (C, D, zinc) support general health but don’t replace G-CSF/antibiotics. Use only with clinician advice. Office of Dietary Supplements

9. Should we use probiotics?
   Often avoided during severe neutropenia due to safety concerns; follow your team’s guidance. Blood Cancer UK

10. What counts as an emergency?
    Any fever ≥38.0°C or rapidly worsening symptoms—seek care immediately for empiric antibiotics. OUP Academic

11. Will antibiotics be needed often?
    They’re used early for fever and targeted for proven infections; choices follow IDSA/ASCO guidance. OUP Academic

12. Can we prevent every infection?
    Not every one, but hand hygiene, food safety, dental care, and prompt fever management markedly reduce risk. PMC

13. Is CXCR2 testing important for family planning?
    Yes—genetic counseling helps families understand autosomal-recessive risks and options. Orpha

14. Are other organs affected?
    Some case series describe additional features in chemokine-axis disorders; care is individualized with comprehensive follow-up. PMC

15. Where can we learn more or find specialists?
    Orphanet and GARD provide rare-disease summaries and links to expert centers and support resources. Orpha+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.